To assess the evidence regarding the availability, cost, and analytical and clinical validity of genetic tests for screening and diagnosis of hereditary cancer predisposing syndromes.
To document the impact of genetic testing (GT) on the clinical management of patients with specific hereditary cancer predisposing syndromes.